Vomiting associated with pentostatin and pentostatin plus alpha-interferon: unique pattern and potential mechanisms

Area of Science:

• Oncology
• Pharmacology

Background:

• Pentostatin (2'-deoxycoformycin) is an antineoplastic agent for lymphoid malignancies.
• Existing data on pentostatin-induced nausea and vomiting (N&V) is insufficient for supportive care recommendations.

Purpose of the Study:

• To evaluate the incidence, duration, and severity of N&V in a phase I study of pentostatin.
• To identify N&V as a potential dose-limiting toxicity.

Main Methods:

• Phase I clinical trial assessing pentostatin, alone and with alpha interferon.
• Systematic recording of N&V incidence, onset, duration, and severity.

Main Results:

• Vomiting incidence increased from 20% (pentostatin alone) to 50% with concurrent alpha interferon.
• Nausea and vomiting was dose-limiting in 6 of 15 patients.
• Delayed onset (>24 hr) and prolonged duration (>48 hr) were common for vomiting episodes.

Conclusions:

• Nausea and vomiting is a significant and potentially dose-limiting toxicity of pentostatin, particularly with combination therapy.
• Delayed and prolonged N&V requires careful consideration for antiemetic management.
• Further research into mechanisms and optimal antiemetic strategies is warranted.